glp-1 controversy for Weight Loss and Diabetes The risks people are not

GSH depletion induced autophagy accompanied by ferroptosis, as well as cell senescence

Licensed indication : The same active ingredient may be marketed under different brand names for diabetes versus obesity (e.g., Ozempic vs Wegovy for semaglutide), with different pricing structures

Health Canada must verify that these manufacturing differences dont compromise safety or effectiveness. Most Realistic Expectation: Pharmaceutical experts suggest that the earliest generic approvals could arrive by mid-2026 or summer , with widespread availability and competitive pricing developing over the remainder of the year as multiple manufacturers enter the market

Additionally, frequent schedule changes can make it difficult to establish the routine adherence that supports long-term treatment success

NAD+ - nicotinamide adenine dinucleotide - is a coenzyme involved in cellular energy metabolism

doi:10.1016/j.smrv.2017.03.005 Mansukhani MP, Kolla BP, Somers VK